CompanyTRDANasdaqBoston, MA

Entrada Therapeutics, Inc.

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines for neuromuscular and inherited retinal diseases.

SEC EDGAR ClinicalTrials.gov entradatx.com

10-KSep 24Latest SEC filing, period to Jun 30

Aug 5Latest story

August 2026

Entrada reports Q2 2026 results with DMD data due by year-end, VX-670 update ahead

Aug 5Quarterly updateEntrada Therapeutics, Inc.

July 2026

Entrada registers Phase 2 long-term extension study for DMD exon skipping drugs

Jul 2Trial updateENTR-601-44 ENTR-601-45